menu
    • menu

    Company profile for Seal Rock Therapeutics

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Seal Rock Therapeutics, Inc. is discovering and developing small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and fibrosis. Seal Rock is currently focusing its efforts on hepatic indications including NASH (non-alcoholic steatohepatitis), a condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to ...
    Seal Rock Therapeutics, Inc. is discovering and developing small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and fibrosis. Seal Rock is currently focusing its efforts on hepatic indications including NASH (non-alcoholic steatohepatitis), a condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to liver fibrosis. Additional opportunities with ASK1 inhibitors include cardiac, immunological and neurodegenerative indications.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Seal Rock TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    500 Yale Ave N Seattle, WA 98109
    Telephone
    Telephone
    786.453.0593
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sealrocktx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Seal Rock Joins MJ Fox Foundation's LITE Program
    Seal Rock Joins MJ Fox Foundation's LITE Program

    13 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/seal-rock-therapeutics-joins-the-michael-j-fox-foundations-lite-program-to-advance-new-therapies-targeting-lrrk2-for-parkinsons-disease-302528368.html

    PR NEWSWIRE
    13 Aug 2025
    Share Share
    Seal Rock To Present SRT-015 Efficacy In Cholestatic Liver Disease
    Seal Rock To Present SRT-015 Efficacy In Cholestatic Liver Disease

    30 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/seal-rock-therapeutics-to-present-preclinical-efficacy-findings-for-srt-015-in-cholestatic-liver-diseases-at-the-european-association-for-study-of-the-liver-easl-congress-2024-302157529.html

    PR NEWSWIRE
    30 May 2024
    Share Share
    Genfit licenses liver failure drug from Seal Rock in $107M deal
    Genfit licenses liver failure drug from Seal Rock in $107M deal

    01 Jun 2023

    // James Waldron FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/genfit-adds-3rd-liver-failure-asset-roster-107m-biobucks-deal-seal-rock

    James Waldron FIERCE BIOTECH
    01 Jun 2023
    Share Share
    Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT
    Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT

    31 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/seal-rock-therapeutics-announces-out-licensing-agreement-with-genfit-for-development-of-injectable-formulation-of-srt-015-for-acute-on-chronic-liver-disease-aclf-301839273.html

    PR NEWSWIRE
    31 May 2023
    Share Share
    Seal Rock Therapeutics Announces Presentations at AASLD's The Liver Meeting 2022
    Seal Rock Therapeutics Announces Presentations at AASLD's The Liver Meeting 2022

    24 Oct 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/seal-rock-therapeutics-announces-upcoming-oral-and-poster-presentations-at-aaslds-the-liver-meeting-2022-301656962.html

    PRNEWSWIRE
    24 Oct 2022
    Share Share
    Seal Rock Announces Completion of Single Ascending DosePh 1 Trial of ASK1SRT-015
    Seal Rock Announces Completion of Single Ascending DosePh 1 Trial of ASK1SRT-015

    19 Oct 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/seal-rock-therapeutics-announces-completion-of-single-ascending-dose-cohort-in-phase-1-clinical-trial-of-ask1-inhibitor-srt-015-for-nash-301403152.html

    PRNEWSWIRE
    19 Oct 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search